ANN – Macquarie rates the stock as Underperform

Fresh guidance provided by Ansell at its AGM implies a 40/60 skew in earnings to the second half compared to a 45/55 average over FY15-19. Macquarie sees price as a more relative factor in the 2H and on current dynamics, retains Sell.

The broker had previously highlighted the benefit of price increases over and above dollar cost pass-through, primarily for examination and single-use products, based on recent trends now sees downside risk to FY22 guidance and consensus expectations.

Target falls to $30.70 from $32.00.

Sector: Health Care Equipment & Services.

 

Target price is $30.70.Current Price is $30.52. Difference: $0.18 – (brackets indicate current price is over target). If ANN meets the Macquarie target it will return approximately 1% (excluding dividends, fees and charges – negative figures indicate an expected loss).

 

 

About Broker News

FNArena's Australian Broker Call, is your daily news report on the latest recommendation, valuation, forecast and opinions recently published by Stockbrokers.

View more articles by Broker News →